This document discusses drug and vaccine discovery efforts for monkeypox. It outlines the workflow for drug repurposing targeting monkeypox, identifying potential existing drugs that could be effective. These include tecovirimat, brincidofovir, and others. It also describes the process for vaccine development, noting existing smallpox vaccines may prevent monkeypox. Finally, it lists the services and products available from Creative Biolabs to support anti-monkeypox drug and vaccine discovery.

1. Monkeypox Drug and
Vaccine Discovery
Copyright © Creative Biolabs. All Rights Reserved.

2. Content
Background of Monkeypox
01
Monkeypox Drug Discovery
02
• Drug Repurposing Strategy (DRS)
• Workflow for Drug Repurposing Targeting Monkeypox Virus
• Potential Drugs Derived for Monkeypox Targets
Monkeypox Vaccine Discovery
03
• Workflow for Vaccine Development Targeting Monkeypox Virus
• Different Vaccines and Their Ways of Producing Immunogen in Cells
• Reported Smallpox Vaccines for Preventing Monkeypox Infections
Creative Biolabs’ Monkeypox Services and Products
04
03

3. Background of Monkeypox
01

4. A new zoonotic illness called monkeypox is brought on by the monkeypox virus (MPXV),
which belongs to the family Poxviridae's Orthopoxvirus genus. Monkeypox symptoms
include a rash, fever, and swelling of the lymph nodes. Additionally, patients may
experience a variety of side effects, such as secondary bacterial infections, respiratory
problems, bronchopneumonia, gastrointestinal problems, dehydration, sepsis, encephalitis,
and corneal infections with subsequent vision loss. No specific treatment for a monkeypox
virus infection currently exists.
Background of Monkeypox
Common(Nonspecofic)
Symptoms
Complications
• Fever
• Headache
• Myalgia
• Backache
• Lymphadenopathy
• Chills
• Exhaustion
• Rashes
• Mouth and throat ulcers
• Bacterial Superinfection
• Corneal Infection/Permanent
Scarring
• Bronchopneumonia
• Sepsis and Septic Shock
• Cellulitis
• Respiratory Distress
• Encephalitis
• Dehydration
04

5. Mutations have enabled the virus to grow stronger and smarter,
evading antiviral drugs and vaccines. To better identify and
control the current monkeypox outbreak, efforts to develop
drugs and vaccines are critical.
Brincidofovir
(TEMBEXA )
Tecovirimat
(TPOXX)
The distribution and number of confirmed monkeypox cases worldwide
Background of Monkeypox
05

6. Monkeypox Drug Discovery
02

7. Drug repurposing is also known as drug repositioning or therapeutic switching. This method is used to
find novel therapeutic agents among the existing FDA-approved clinically used drug molecules. It is
considered an efficient approach to developing drug candidates with new pharmacological activities or
therapeutic properties. As drug discovery is a costly, time-consuming, laborious, and highly risky process,
the novel approach of drug repositioning is employed to increase the success rate of drug development.
Repurposing old drugs seems like a good idea against the monkeypox virus due to the emergency of the
actual situation.
Drug Repurposing Strategy (DRS)
?
07

8. Sequence Identification and Alignment Generating 3D-Models (Protein Modeling)
Obtainment of Native Structures
(Dynamics Simulations)
（Edeildo, F, et al., 2022)
Filtering FDA-Approved Drugs
Affinity Energies
(Molecular Docking)
Experimental Validation
of Repurposed Drugs
Publicizing of
All Validated Results
Workflow for Drugs Repurposing Targeting Monkeypox Virus
08

9. Gene Protein Function Reference Protein In Vitro Proven Drug Novel Repurposable Drug Drug Structure
A48R Thymidylate kinase PDB: 2V54 -
NMCT
Rutaecarpine
A50R DNA ligase
AlphaFold2 structure of German
monkeypox viral protein identified
via tBLASTn
Mitoxantrone Nilotinib
D13L Viral capsid protein PDB: 6BED Rifampin Simeprevir
F13L EEV formation protein
AlphaFold2 structure of German
monkeypox viral protein identified
via tBLASTn
Tecovirimat
Hypericin
Naldemedine
I7L Protease
AlphaFold2 structure of German
monkeypox viral protein identified
via tBLASTn
TTP6171
Fosdagrocorat
Lixivaptan
(Lam, H, et al., 2022)
Potential Drugs Derived for Monkeypox Targets
09

10. Monkeypox Vaccine Discovery
03

11. Workflow for Vaccine Development Targeting Monkeypox Virus
1、Sequence viral
and host genomes
2、Selest vaccine targets
based on bioinformatic
analysis
3、Clone vaccine targets
4、Express & purify vaccine
targets
5、Immunize mice width vaccine targets
6、Screen immune sera for
antiviral activity and
optimize vaccine candidates
7、Conduct clinical trials
with selected final vaccine candidates
11

12. (Yingzhu, L, et al., 2021)
Different Vaccines and Their Ways of
Producing Immunogen in Cells
12

13. (Abdelaziz, A, et al., 2022)
Vaccine Generation Effective for
Use for
Monkeypox
Structure
JYNNEOSTM 3rd generation
General adult
population
Yes (USA, UK,
Canada)
Nonreplicating
vaccinia virus
ACAM2000
2nd
generation
Adults (18–64)
USA:
postexposure
prophylaxis
Propagated in tissue
cell culture and
produced under
good manufacturing
practices (live,
replication-
competent virus)
Reported Smallpox Vaccines for Preventing
Monkeypox Infections
13

14. Creative Biolabs' Monkeypox
Services and Products
04

15. • Neutralizing Antibody-based Anti-Monkeypox Drug Discovery Solutions
• Artificial Intelligence-Based Anti-monkeypox Drug Discovery Solutions
• Anti-Monkeypox Drug Discovery In Vitro Assays
• Anti-Monkeypox Drug Discovery In Vivo Assays in Animal Models
• Vaccine-Based Anti-monkeypox Drug Discovery Solutions
• Monkeypox Recombinant Proteins and Peptides
• Monkeypox Antibodies
• Monkeypox Detection Kits
• Monkeypox Plasmids
• Monkeypox Primers and Probes
• Monkeypox Pseudovirus
• Monkeypox Inhibitors
Creative Biolabs’ Monkeypox Services and Products
Services：
Products：
15

16. Tel: 1-631-357-2254
info@creative-biolabs.com
SUITE 203, 17 Ramsey Road, Shirley, NY 11967, USA
Copyright © Creative Biolabs. All Rights Reserved.